

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute of form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT NOV 13 2003 (use as many sheets as necessary)		Complete if Known	
Application Number		10/602,521	
Filing Date		June 24, 2003	
First Name Inventor		David Edwin Thurston	
Group Art Unit		1624	
Examiner Name			
Attorney Docket Number		065435-9027	

U.S. PATENT DOCUMENTS			
Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
/J.E./	4,239,683	Yoshio Arakawa	12/16/1980
↓	3,524,849	Batcho <i>et al.</i>	8/18/1970
↓	3,523,941	Leimgruber <i>et al.</i>	8/11/1970
↓	5,545,568	Ellman	8/13/1996
↓	4,309,437	Ueda <i>et al.</i>	1/1982


FOREIGN PATENT DOCUMENTS						
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
/J.E./	JP	JP 58 180 487	Kyowa Hakko Kogyo Co. Ltd.	10/21/1983		
↓	JP	JP 57 131 791	Fujisawa Yakuhin Kogyo KK	8/14/1982		
↓	FR	FR 2 586 683	Centre National de la Recherche Scientifique	3/6/1987		
↓	GB	GB 1 299 198		12/6/1972		
↓	WO	WO 92/19620	Centre National de la Recherche Scientifique	11/12/1992		
↓	WO	WO 97/01560	Pharmacoepia, Inc.	1/16/1997		

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet	1	of	8	Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
				Attorney Docket Number	065435-9027

Complete if Known**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
No Titles		Althuis, T.H. and Hess, H.J, <i>J. Medicinal Chem.</i> , 20(1), 146-149 (1977).
		<i>Arima et al., J. Antibiotics</i> , 25, 437-444 (1972).
		<i>Aristoff, J. Org. Chem.</i> , 57, 6234-6239 (1992).
No Titles		Baraldi, P. G. <i>et al.</i> , "Design, synthesis and biological activity of a pyrrolo [2,1-c] [1,4]benzodiazepine (PBD)-distamycin hybrid", <i>Bioorganic & Medicinal Chemistry Letters</i> , vol. 8, no. 21, 3019-3024 (1998).
		Bi, Y., <i>et al.</i> , <i>Bioorganic & Medicinal Chemistry Letters</i> , vol. 6, no. 19, 2299-2300 (1996).
		Boger <i>et al.</i> , <i>Chem. Rev.</i> , 97, 787-828 (1997).
		Bose <i>et al.</i> , <i>Tetrahedron</i> , 48, 751-758 (1992)
		Bose, D.S., <i>et al.</i> , <i>J. Am. Chem. Soc.</i> 1992, 114, 4939-4941.

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for Form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 8

Complete if Known

Application Number	10/602,521
Filing Date	June 24, 2003
First Named Inventor	David Edwin Thurston
Group Art Unit	1624
Examiner Name	
Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

No Title

~~Brown, S C et al., Science, 265, 777 (1994).~~

/J.E./ Burgess, K. et al., "Solid Phase Synthesis of Oligoureas", *Journal of the American Chemical Society*, 119: 1556-64 (1997).

/J.E./ Burgess, K. et al., "Solid Phase Synthesis of Unnatural Biopolymers Containing Repeating Urea Units" *Agnew Chem. Int. Ed. Engl.* 34, No. 8:907 (1995).

No Title

~~Cava et al., Drost, K. J., Cava, M. P., J. Org. Chem., 56, 2240-2244 (1991).~~

/J.E./ Chemical Abstract No. 171573p, O'Neil, "The synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines", *Chemical Abstracts*, vol. 126, no. 13, 618 (1997) and entire article.

/J.E./ Chemical Abstract No. 239940r, Farmer, "DNA binding properties of a new class of linked anthramycin analogs", *Chemical Abstracts*, vol. 114, no. 25, 25 (1991) and entire article.

/J.E./ Chemical Abstract No. 4427a, Umezawa, "Mazethramycins" *Chemical Abstracts*, vol. 90, no. 1, 428 (1979).

/J.E./ Chemical Abstract No. 72145x, Fujisawa, "Benzodiazepine derivatives", *Chemical Abstracts*, vol. 98, no. 9, 638 (1983).

/J.E./ Chemical Abstracts No. 139983k, Fujisawa, *Chemical Abstracts*, vol. 99, no. 17, 603 (1983).

Examiner
Signature

/Jon Epperson/

Date
Considered

09/16/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV 13 2003

PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	3	of	8	Attorney Docket Number	065435-9027


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		Chemical Abstracts, Yingzhi, Bi. <i>et al.</i> , "Building blocks for peptide and carbamate libraries", <i>Chemical Abstracts</i> , vol. 125, no. 23, 1013 (1996).
/J.E./		Cho, C Y <i>et al.</i> , "An Unnatural Biopolymer", <i>Science</i> , 261: 1303-5 (1993).
/J.E./		Courtney, S. M. <i>et al.</i> , "A new convenient procedure for the synthesis of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Tetrahedron Letters</i> , vol. 34, no. 33, 5327-28 (1993).
/J.E./		Damayanthi, Y., <i>et al.</i> , "Design and synthesis of novel pyrrolo{2,1-c}[1,4] benzodiazepine-Lexitropsin Conjugates," <i>J. Org. Chem.</i> , 64, 290-292 (1999).
		Edman, P. and Begg, G., <i>Eur. J. Biochem.</i>, 1, 80 (1967).
/J.E./		Figliozzi, GMR <i>et al.</i> , "Synthesis of N-substituted Glycine Peptoid Libraries", <i>Methods in Enzymology</i> , 267, 437-47 (1996).
/J.E./		Foloppe, M.P., <i>et al.</i> , "DNA-binding properties of pyrrolo[2,1-c][1,4]benzodiazepine N10-C11 amidines" <i>Eur. J. Med. Chem.</i> , 31, 407-410 (1996).
/J.E./		Fukuyama, T. <i>et al.</i> , "Total synthesis of (+)-porothramycin B", <i>Tetrahedron Letters</i> , vol. 34, no. 16, 2577-2580 (1993).
/J.E./		Furka, A. <i>et al.</i> , <i>International Journal of Peptide and Protein Research</i> , 37, 487-493 (1991).

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	4	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS


Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		Gregson, S. J. <i>et al.</i> , "Synthesis of a novel C2/C2' -exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity", <i>Chemical Communications</i> , 797-798 (1999).
/J.E./		Guiotto A. <i>et al.</i> , "Synthesis of novel C7-aryl substituted pyrrolo [2,1-c] [1,4]benzodiazepines (PBDs) via Pro-N10-troc protection and suzuki coupling", <i>Bioorganic & Medicinal Chemistry Letters</i> , vol. 8, no. 21, 3017-3018 (1998).
No Titles		Hara <i>et al.</i> , <i>J. Antibiotics</i> , 41, 702,704 (1988).
		Hara <i>et al.</i> , <i>J. Antibiotics</i> , 41, 1366-1373 (1988).
		Hochlowski <i>et al.</i> , <i>J. Antibiotics</i> , 40, 145-148 (1987).
		Hurley and Needham-VanDevanter, <i>Acc. Chem. Res.</i> , 19, 230-237 (1986).
		Itoh <i>et al.</i> , <i>J. Antibiotics</i> , 41, 1281-1284 (1988).
		Jenkins, T.C., <i>et al.</i> , <i>J. Med. Chem.</i> 1994, 37, 4529-4537
		Kohn, <i>Antibiotics III</i> , Springer-Verlag, NY, 3-11 (1975).

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	5	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		Konishi <i>et al.</i> , <i>J. Antibiotics</i> , 37, 200-206 (1984).
		Kunimoto <i>et al.</i> , <i>J. Antibiotics</i> , 33, 665-667 (1980).
		Langley and Thurston, <i>J. Org. Chem.</i> , 52, 91-97 (1987).
No Titles		Leber <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 110, 2992-2993 (1988).
		Leimgruber <i>et al.</i> , <i>J. Am. Chem. Soc.</i> , 87, 5791-5793 (1965).
		Leimgruber <i>et al.</i> , <i>Am. Chem. Soc.</i> , 87, 5793-5795 (1965).
		Lescrinier, <i>et al.</i> , <i>Chem. Eur. J.</i> , 425-433 (1998).
		Lown <i>et al.</i> , <i>Biochem. Pharmacol.</i> (1979), 28 (13), 2017-26; Abstract
		M Egholm <i>et al.</i> , <i>JACS</i> , 114, 1895 (1992).

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

NOV 13 2003
 OIPE
 PATENT & TRADEMARK OFFICE

PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for Form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1624
				Examiner Name	
Sheet	6	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
		M Egholm <i>et al.</i> , <i>Nature</i> , 365, 566 (1993).
		Monks, A. <i>et al.</i> , <i>Journal of National Cancer Institute</i> , 83, 757 (1991).
		Moran, E J, <i>et al.</i> , "Novel Biopolymers for Drug Discovery. Biopolymers", <i>Peptide Science, John Wiley and Sons</i> , 37: 213-19 (1995)
		Nagasaka, T. <i>et al.</i> , "Stereoselective synthesis of Tilivalline", <i>Tetrahedron Letters</i> , vol. 30, no. 14, 1871-72 (1989).
		Nagasaka, T. <i>et al.</i> , "Stereoselective synthesis of tilivalline", <i>Journal of Organic Chemistry</i> , vol. 36, no. 20, 6797-6801 (1998).
		Nielson, P E <i>et al.</i> , <i>Science</i> , 254, 1497 (1991).
		O'Neil, I. A. <i>et al.</i> , "DPPE: A Convenient Replacement for Triphenylphosphine in the Staudinger and Mitsunobu Reactions", <i>Tetrahedron Letters</i> , vol. 39, no. 42, 7787-7790 (1998). ,
		Paikoff, S F <i>et al.</i> , "The Solid Phase Synthesis of N-Alkylcarbamate Oligomers", <i>Tetrahedron Letters</i> , 37, No. 32: 5653-56 (1996).
		Rawal, V. H., Jones, R. J., Cava, M. P., <i>J. Org. Chem.</i> , 52, 19-28 (1987).

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

OIPE
 NOV 13 2003
 PATENT & TRADEMARK OFFICE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form PTO 449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
Application Number				10/602,521	
Filing Date				June 24, 2003	
First Named Inventor				David Edwin Thurston	
Group Art Unit				1624	
Examiner Name					
Attorney Docket Number				065435-9027	
Sheet	7	of	8		


OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
No Titles		Saha K. <i>et al.</i> , <i>JOC</i> , 58, 7827 (1993).
		Schreiber <i>et al.</i> , <i>JACS</i> , 120, 23-29 (1998)
		Shimizu <i>et al.</i> , <i>J. Antibiotics</i> , 29, 2492-2503 (1982).
No Titles		Simon, R. J. <i>et al.</i> , "Peptoids: A Modular Approach to Drug Discovery", <i>Proc. Natl. Acad. Sci. USA</i> , 89, 9367-71 (1992).
		Soth, M. J. and Nowick, J. S., "Unnatural oligomer libraries", <i>Curr. Opin. Chem. Biol.</i> , 1, 120-129 (1997).
		Takeuchi <i>et al.</i> , <i>J. Antibiotics</i> , 29, 93-96 (1976)
		Thurston <i>et al.</i> , <i>Chem. Brit.</i> , 26, 767-772 (1990).
		Thurston <i>et al.</i> , <i>Chem. Rev.</i> , 1994, 433-465 (1994).
		Thurston, D. E. <i>et al.</i> , "Synthesis of a novel GC-specific covalent-binding DNA affinity-cleavage agent based on pyrrolobenzodiazepines", <i>Chemical Communications</i> , 563-565 (1996).

Examiner Signature	/Jon Epperson/	Date Considered	/Jon Epperson/
--------------------	----------------	-----------------	----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1624	
			Examiner Name		
Sheet	8	of	8	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	/J.E./	Thurston, D. E., <i>et al.</i> , "Effect of A-ring modifications on the DNA-binding behavior and cytotoxicity of pyrrolo[2,1-c][1,4]benzodiazepines", <i>Journal of Medicinal Chemistry</i> , vol. 42, 1951-1964 (1999).
	/J.E./	Thurston, D.E., "Advances in the study of Pyrrolo[2,1-c][4,1] benzodiazepine (PBD) Antitumour Antibiotics", <i>Molecular Aspects of Anticancer Drug-DNA interactions</i> , Neidle, S., Waring, M.J. eds., Macmillan Press Ltd., 1: 54-88 (1993).
		Tsunakawa, <i>et al.</i>, <i>J. Antibiotics</i>, 41, 1366-1373 (1988).
	/J.E./	Wilson, S. C. <i>et al.</i> , "Design and Synthesis of a Novel Epoxide-Containing Pyrrolo[2,1-c][1,4]benzodiazepine (PBD) via a New Cyclization Procedure", <i>Tetrahedron Letters</i> , vol. 36, no. 35, 6333-6336 (1995).
	/J.E./	Zuckermann <i>et al.</i> , "Discovery of Nanomolecular Ligands for 7-Transmembrane G-Protein-Coupled Receptors from a Diverse N-(Substituted) glycine Peptoid Library", <i>Journal of Medicinal Chemistry</i> , 37, 2678-85 (1994).

Q:\client\065435\9027\B0251878.1

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1639
				Examiner Name	Epperson, Jon D.
Sheet	1	of	1	Attorney Docket Number	065435-9027

U.S. PATENT DOCUMENTS

Examiner Initials		U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
/J.E./		4,185,016	Takanabe et al.	1/22/1980
		5,143,854	Pirung et al.	9/1/1992
		6,747,144	Thurston et al.	6/8/2004
		6,562,806	Thurston et al.	5/13/2003
		6,608,192	Thurston et al.	8/19/2003
		2003-0120069	Thurston et al.	6/26/2003
		2003-0195196	Thurston et al.	10/16/2003

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
/J.E./	WO	88/07378	Cancer Research Campaign Technology Ltd.	10/6/1988		
	WO	89/10140	Cancer Research Campaign Technology Ltd.	11/2/1989		
	WO	93/08288	Cancer Research Campaign Technology Ltd.	4/29/1993		
	WO	93/18045	Cancer Research Campaign Technology Ltd.	9/16/1993		
	WO	00/12506	The University of Portsmouth Higher Education Corp.	3/9/2000		
	WO	00/12507	The University of Portsmouth Higher Education Corp.	3/9/2000		
	EP	0239400A2	Winter, G.P.	9/30/1987		
	FR	2027356	Fujisawa Pharmaceutical Co. Ltd.	12/29/1969		
	JP	53-82792	Microbiological Chemical Research	7/21/1978		

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Epperson, Jon D.	
Sheet	1	of	6	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		ALBERICIO, F. et al., "NPE-Resin, A New Approach to the Solid-Phase Synthesis of Protected Peptides and Oligonucleotides II. Synthesis of Protected Peptides ^{1,2} ," <i>Tetrahedron Letters</i> , 32:1515-1518 (1991)
	↓	ALBERICIO, F. et al., "NPE-resin, a new approach to the solid-phase synthesis of protected peptides and oligonucleotides," <i>Peptides</i> 1990, Proc. 21.sub.st Eur. Pept. Symp., 134-136 (1990)
	↓	BAGSHAWE et al., "Antibody-Enzyme Conjugates Can Generate Cytotoxic Drugs from Inactive Precursors at Tumor Sites," <i>Antibody, Immunoconjugates, and Radiopharmaceuticals</i> , 4, 915-922 (1991)
	↓	BARALDI, P.G. et al., "Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c][1,4]benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers," <i>J. Med. Chem.</i> , 42, 5131-5141 (1999)
		BAYLEY, H. et al., "Photoactivatable drugs," <i>TIPS</i>, 8, 138-143 (1987)
/J.E./		BERRY, J. M. et al., "Solid-phase synthesis of DNA-interactive pyrrolo[2,1-c][1,4]benzodiazepines," <i>Tetrahedron Letters</i> , 41, 6171-6174 (2000)
/J.E./		BRIDGES, R.J. et al., "Conformationally Defined Neurotransmitter Analogues. Selective Inhibition of Glutamate Uptake by One Pyrrolidine-2,4-dicarboxylate Diastereomer," <i>J. Med. Chem.</i> , 34, 717-725 (1991)
/J.E./		BUNDGAARD, H., "Design and Application of Prodrugs," <i>A Textbook of Drug Design and Development</i> , eds Krogsgaard-Lassen, P., and Bundgaard, H., Harwood Academic Press, 113-135 (1991)
/J.E./		CARRUTH, J.A.S., "Clinical applications for photodynamic therapy," <i>J. Photochem Photobiol.</i> , 9, 396-397 (1991)

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Epperson, Jon D.	
Sheet	2	of	6	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	/J.E./	CULVER et al., "In Vivo Gene Transfer with Retroviral Vector-Producer Cells for Treatment of Experimental Brain Tumors," <i>Science</i> , 256, 1550-1552 (1992)
		DALTON, S. and TREISMAN, R., "Characterization of SAP-1, a Protein Recruited by Serum Response Factor to the c-fos Serum Response Element," <i>Cell</i> , 68, 597-612 (1992)
		DANGLES, O. et al., "Selective Cleavage of the Allyl and Allyloxycarbonyl Groups through Palladium-Catalyzed Hydrostannolysis with Tributyltin Hydride. Application to the Selective Protection-Deprotection of Amino Acid Derivatives and in Peptide Synthesis," <i>J. Org. Chem.</i> , 52, 4984-4993 (1987)
		DRESSMAN, B.A., et al., "Solid Phase Synthesis of Hydantoins Using a Carbamate Linker and a Novel Cyclization/Cleavage Step," <i>Tetrahedron Letters</i> , 37, 937-940 (1996)
		EASHOO, M. et al., "Fibers from a Low Dielectric Constant Fluorinated Polyimide: Solution Spinning and Morphology Control," <i>J. Polymer Science</i> , 35:173-185 (1997)
		ENGLEHARDT et al., "Direct gene transfer of human CFTR into human bronchial epithelia of xenografts with E1-deleted adenoviruses," <i>Nature Genetics</i> , 4, 27-34 (1993)
		FUJISAWA PHARMACEUTICAL CO., LTD., "Benzodiazepine derivatives," <i>SciFinder Scholar</i> , 2-3 (2002)
		GARCIA-ECHEVERRIA, C., "A Base Labile Handle for Solid Phase Organic Chemistry", <i>Tetrahedron Letters</i> , 38,52, 8933-8934 (1997)
	↓	GRANT, R. et al., <i>Grant and Hackh's Chemical Dictionary</i> , McGraw-Hill Book Company, 282 (1987)

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Epperson, Jon D.	
Sheet	3	of	6	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	/J.E./	GREENE, T.W. and WUTS, P.G.M., <i>Protective Groups in Organic Synthesis</i> , John Wiley & Sons, 2 nd ed., Ch 7, 315-345 (1991)
		GREGSON, S.J. et al., "Design, Synthesis and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity", <i>J. Med. Chem.</i> , 44: 737-748 (2001)
		GREGSON, S.J. et al., "Effect of C2- <i>exo</i> Unsaturation on the Cytotoxicity and DNA-Binding Reactivity of Pyrrolo[2,1- <i>c</i>]1,4]benzodiazepines", <i>Bioorganic & Medicinal Chemistry Letters</i> , 10: 1845-1847 (2000)
		HAUSKE, J. R. and DORFF, P., "Solid Phase CBZ Chloride Equivalent. A New Matrix Specific Linker", <i>Tetrahedron Letters</i> , 36, 10, 1589-1592 (1995)
		HOCART et al., "Highly potent cyclic disulfide antagonists of somatostatin," <i>J. of Medicinal Chem.</i> , 42:11 (1999)
		HOLMES, C.P. and JONES, D.G., "Reagents for Combinatorial Organic Synthesis: Development of a New O-Nitrobenzyl Photolabile Linker for Solid Phase Synthesis", <i>J. Org. Chem.</i> , 60, 2318-2319 (1995)
		HUBER, B. et al., "Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy," <i>Proc. Natl. Acad. Sci. USA</i> , 88, 8039-8043 (1991)
		JUNGHEIM, L.N. and SHEPHERD, T.A., "Design of Antitumor Prodrugs: Substrates for Antibody Targeted Enzymes," <i>Am. Chem. Soc. Chem. Rev.</i> , 94, 1553-1566 (1994)
	✓	KAMAL, A., et al., "An Efficient Synthesis of Pyrrolo[2,1- <i>c</i>][1,4] Benzodiazepine Antibiotics via Reductive Cyclization," <i>Bioorg. Med. Chem. Ltrs</i> , 7, No. 14, 1825-1828 (1997)

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Epperson, Jon D.	
Sheet	4	of	6	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	/J.E.	KAMAL, A., et al., "Synthesis of Pyrrolo [2,1-c][1,4]-Benzodiazepene Antibiotics: Oxidation of Cyclic Secondary Amine with TPAP", <i>Tetrahedron</i> , v. 53, No. 9, 3223-3230 (1997)
		KAPOOR, T.M. et al., "Exploring the Specificity Pockets of Two Homologous SH3 Domains Using Structure-Based, Split-Pool Synthesis and Affinity-Based Selection," <i>J. Am. Chem. Soc.</i> 120:23-29 (1998)
		KATRITZKY et al., <i>Heterocyclic Chemistry</i> , John Wiley & Sons, Inc., 247-253 (1960)
		KENNEDY, J.C. and POTTIER, R.H., "Endogenous protoporphyrin IX, a clinical useful photosensitiser for photodynamic therapy," <i>J. Photochem Photobiol</i> , 14, 275-292 (1992)
		KUNZ, H. and DOMBO, B., "Solid Phase Synthesis of Peptide and Glycopeptides on Polymeric Supports with Allylic Anchor Groups," <i>Angew Chem. Int. Ed. Engl</i> , 5, 711-713 (1988)
		KUZMICH, S. et al., "Increased levels of glutathione S-transferase π transcript as a mechanism of resistance to ethacrynic acid," <i>Journal of Biochemistry</i> , 281, 219-224 (1992)
		LEIMGRUBER, W. et al., "Total synthesis of anthramycin," <i>J. Am. Chem. Soc.</i> , 90, 5641-5643 (1968)
		LEWIS A.D. et al., "Glutathione and glutathione-dependent enzymes in ovarian adenocarcinoma cell lines derived from a patient before and after the onset of drug resistance: intrinsic differences and cell cycle effects," <i>Carcinogenesis</i> , 9, 1283-1287 (1988)
	↓	MIZUSHIMA, S. and NAGATA, S., "pEF-BOS, a powerful mammalian expression vector," <i>Nucl. Acids Res.</i> , 18, 5322 (1990)

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary).			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Epperson, Jon D.	
Sheet	5	of	6	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	/J.E./	MORGAN, R.A. and ANDERSON, W.F., "Human Gene Therapy," <i>Annu. Rev. Biochem.</i> , 62, 191-217 (1993)
		MOSMANN, T., "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <i>J. Immunological Methods</i> , 65, 55-63 (1983)
		MULLEN, D.G. and BARANY, G., "A New Fluoridolizable Anchoring Linkage for Orthogonal Solid-Phase Peptide Synthesis: Design, Preparation, and Application of the N-(3 or 4)-[[4-(Hydroxymethyl) phenoxy]-tert-butylphenylsilyl]phenyl Pentanedioic Acid Monoamide (Pbs) Handle", <i>J. Org. Chem.</i> , 53, 5240-5248 (1988)
		NICOLAOU, K.C. et al., "Designed Enediynes: A New Class of DNA-Cleaving Molecules with Potent and Selective Anticancer Activity," <i>Science</i> , 256, 1172-1178 (1992)
		O'NEIL, I.A., et al., "The Synthesis of Functionalized Pyrrolo-[2,1-c][1,4]-Benzodiazepines," <i>Synlett</i> , 75-78 (1997)
		PILLAI, V.N.R., "Photoremovable protecting groups in organic chemistry," <i>Synthesis</i> , 1-26 (1980)
		RAM, Z. et al., "In Situ Retroviral-mediated Gene Transfer for the Treatment of Brain Tumors in Rats," <i>Cancer Research</i> , 53, 83-88 (1993)
		REGULA, J. et al., "Photosensitisation and photodynamic therapy of oesophagael, duodenal and colorectal tumours using 5-aminolevulinic acid induced photoporphyrin IX-a pilot study," <i>Gut</i> , 36, 67-75 (1995)
	↓	SAGNOU, M.J. et al., "Design and Synthesis of Novel Pyrrolobenzodiazepine (PDB) Prodrugs for ADEPT and GDEPT," <i>Bioorganic & Medicinal Chemistry Letters</i> , 10, 2083-2086 (2000)

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1639
				Examiner Name	Epperson, Jon D.
Sheet	6	of	6	Attorney Docket Number	065435-9027

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
	/J.E./	SATYAM, A. et al., "Design, Synthesis, and Evaluation of Latent Alkylating Agents Activated by Glutathione S-Transferase," <i>J. Med. Chem.</i> , 39, 1736-1747 (1996)
		SHIMIZU, K et al., "Prothracarcin, a Novel Antitumor Antibiotic," <i>J. Antibiotics</i> , 35, 972-978 (1982)
		STAR, W.M., "Light delivery and light dosimetry for photodynamic therapy," <i>Lasers in Medical Science</i> , 5:107-113 (1990)
		SUGGS, J.W. et al., "Synthesis and structure of anthramycin analogs via hydride reduction of dilactams," <i>Tetrahedron Letters</i> , 26, No. 40, 4871-4874 (1985)
		TEW, K.D. and CLAPPER, M.L., "Glutathione-S-transferase and anti-cancer drug resistance," <i>Mechanism of Drug Resistance in Neoplastic Cells</i> , Woolley, P.V. and Tew, K.D., Eds, Academic Press: Sand Diego, CA 141-159 (1988)
		THURSTON, D.E. et al., "Synthesis of Sequence-selective C8-linked Pyrrolo [2,1-c][1,4] Benzodiazepine DNA Interstrand Cross-linking Agent," <i>J. Org. Chem.</i> , 61:8141-8147 (1996)
		UMEZAWA, H. et al., "Mazethramycins," <i>SciFinder Scholar</i> , 2-3 (2002)
		WILSON, S.C. et al., "Design, Synthesis, and Evaluation of a Novel Sequence-Selective Epoxide-Containing DNA Cross-Linking Agent Based on the Pyrrolo[2,1-c][1,4]benzodiazepine System", <i>J. Med. Chem.</i> 42:4028-4041 (1999)
	↓	<i>Dictionary of Science and Technology</i> , Professor P.M.B. Walker ed. Larousse plc., pp. 63, 457, 523 (1995)

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

APR 26 2006

PTO/SB/08A

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449, PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/602,521
Filing Date	June 24, 2003
First named Inventor	David Edwin Thurston
Group Art Unit	1639
Examiner name	Unknown
Attorney Docket Number	065435-9027-US00

U.S. Patent Documents

Examiner Initials	U.S. Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document
/J.E./	6,660,856	Wang	12/9/2003

FOREIGN PATENT DOCUMENTS

Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract
/J.E./	EP	1193270	Spirogen Ltd.	4/3/2002		
	GB	2053894	The Green Cross Corporation	2/11/1981		
	WO	88/04659	The Upjohn Company	6/30/1988		
	WO	91/16324	The Upjohn Company	10/31/1991		
	WO	96/23497	Synphar Laboratories, Inc.	8/8/1996		
	WO	97/07097	Auckland Division Cancer Society of New Zealand Inc.	2/27/1997		
	WO	98/11101	Auckland Division Cancer Society of New Zealand Inc.	3/19/1998		
	WO	98/12197	Kyorin Pharmaceuticals Co., Ltd. et al.	3/26/1998	N	Y
	WO	99/29642	The Scripps Research Institute	6/17/1999		
	WO	99/46244	Novo Nordisk A/S et al.	9/16/1999		

Examiner
Signature

/Jon Epperson/

Date
Considered

09/16/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 2 of 2				Complete if Known			
				Application Number		10/602,521	
				Filing Date		June 24, 2003	
				First named Inventor		David Edwin Thurston	
				Group Art Unit		1639	
				Examiner name		Unknown	
				Attorney Docket Number		065435-9027-US00	
U.S. Patent Documents							
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Country Code	Foreign Patent Document Number	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Translation	English Abstract	
/J.E./	WO	00/12508	The University of Portsmouth Higher Education Corp.	3/9/2000			
↓	WO	00/12509	The University of Portsmouth Higher Education Corp.	3/9/2000			
	WO	00/64864	Cancer Campaign Research Technology Ltd.	11/2/2000			
	WO	2004/043963	Spirogen Ltd.	5/27/2004			
	WO	2005/023814	Spirogen Ltd.	3/17/2005			
	WO	2005/040170	Government of the U.S.A. et al.	5/6/2005			
↓	WO	2005/085251	Spirogen Ltd.	9/15/2005			

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer. Patent and Trademark Office, Washington, DC 0231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box Alexandria, VA 22313-1450.

APR 26 2006

PTO/SB/08B

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	10/602,521
Filing Date	June 24, 2003
First Named Inventor	David Edwin Thurston
Group Art Unit	1639
Examiner Name	Unknown
Attorney Docket Number	065435-9027-US00

Sheet 1 of 5

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTSExaminer
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.

/J.E./

ADAMS et al., "Molecular modelling of a sequence-specific DNA-binding agent based on the pyrrolo[2,1-c][1,4]benzodiazepines," Pharm. Pharmacol. Commun. (1999) 5:555-560

BARALDI, P.G. et al., "[2,1-c][1,4]benzodiazepine (PBD)-distamycin hybrid inhibits DNA binding to transcription factor Sp1," Nucleotides and Nucleic Acids (2000) 19(8):1219-1229

BERGE et al., "Pharmaceutical Salts," J. Pharm. Sci. (1977) 66:1-19

BORGATTI, M. et al., "Inhibition of NF-kB/DNA interactions and HIV-1 LTR directed transcription by hybrid molecules containing pyrrolo [2,1-c][1,4] benzodiazepine (PBD) and oligopyrrole carriers," Drug Development Research (2003) 60(3):173-185

BOSE, D.S. et al., "Effect of linker length on DNA-binding affinity, cross-linking efficiency and cytotoxicity of C8 linked pyrrolobenzodiazepine dimers," J. Chem. Soc. Chem. Commun. (1992) 20:1518-1520

CHEN, Z. et al., "A novel approach to the synthesis of cytotoxic C2-C3 unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs) with conjugated acrylyl C2-substituents," Biorg. Med. Chem. Lett. (2004) 14:1547-1549

COOPER, N. et al., "Synthesis of novel PBDs as anti-tumour agents," Chem. Commun. (2002) 16:1764-1765

DE GROOT, FMH et al., "Synthesis and biological evaluation of 2'-carbamate-linked 2'-carbonate-linked prodrugs of paclitaxel: selective activation by the tumor-associated protease plasmin," J. Med. Chem. (2000) 43(16):3093-3102

DE GROOT, FMH et al., "Novel 20-carbonate linked prodrugs of camptothecin and 9-aminocamptothecin designed for activation by tumour-associated plasmin," Biorg. Med. Chem. Lett. (2002) 12(17):2371-2376

Examiner
Signature

/Jon Epperson/

Date
Considered

09/16/2007

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Unknown	
Sheet	2	of	5	Attorney Docket Number	065435-9027-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		DUBOWCHIK, G.M. et al., "Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin," Biorg. Med. Chem. Lett. (1998) 8:3341-3346
		DUBOWCHIK, G.M. et al., "Cathepsin B-sensitive dipeptide prodrugs. 2. Models of anticancer drugs paclitaxel (Taxol), Mitomycin C and Doxorubicin," Biorg. Med. Chem. Lett. (1998) 8:3347-3352
		DUBOWCHIK and WALKER, "Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs," Pharmacology and Therapeutics (1999) 83:67-123
		GARSKY et al., "The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy," J. Med. Chem. (2001) 44:4216-4224
		GREGSON, S.J. et al., "Effect of C2/C3-endo unsaturation on the cytotoxicity and DNA-binding reactivity of pyrrolo-[2,1-c][1,4]-benzodiazepines," Bioorg. Med. Chem. Lett. (2000) 10(16):1849-1851
		GREGSON, S.J. et al., "Linker length modulates DNA cross-linking reactivity and cytotoxic potency of C8/C8' ether-linked C2-exo-unsaturated pyrrolo[2,1-c][1,4]benzodiazepine (PBD) dimers," J. Med. Chem. (2004) 1161-1174
		GREGSON, S.J. et al., "Synthesis of the first example of a C2-C3/C2'-C3'-endo unsaturated pyrrolo[2,1-c][1,4]benzodiazepine dimer," Biorg. Med. Chem. Lett. (2001) 11:2859-2862
		GREGSON, S.J. et al., "Synthesis of the first examples of A-C8/C-C2 amide-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers," Biorg. Med. Chem. Lett. (2003) 13:2277-2280
	↓	HAMBURGER, A.W. et al., "Primary bioassay of human tumor stem cells," Science (1977) 197:461-643

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/602,521
				Filing Date	June 24, 2003
				First Named Inventor	David Edwin Thurston
				Group Art Unit	1639
				Examiner Name	Unknown
Sheet	3	of	5	Attorney Docket Number	065435-9027-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		JAKOBSEN et al., "Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells," J. Med. Chem. (2001) 44:4696-4703
		KAMAL et al., "Synthesis and DNA-binding affinity of A-C8/C-C2 alkoxyamido-linked pyrrolo[2,1-c][1,4]benzodiazepine dimers" Biorg. Med. Chem. Lett. (2003) 13(22):3955-3958
		KAMAL, et al., "Synthesis of pyrrolo[2,1-c][1,4]benzodiazepines via reductive cyclization of w-azido carbonyl compounds by TMSI: an efficient preparation of antibiotic DC-81 and its dimers," Biorg. Med. Chem. Lett. (2000) 10:2311-2313
		KANEKO, T. et al., "Bicyclic and tricyclic analogues of anthramycin," J. Med. Chem. (1985) 28:388-392
		KANG, G.-D. et al., "Synthesis of a novel C2-aryl substituted 1,2-unsaturated pyrrolobenzodiazepine," Chem. Commun. (2003) 1688-1689
		KUMAR, R. et al., "Synthesis and antitumor cytotoxicity evaluation of novel pyrrolo[2,1-c][1,4]benzodiazepine imidazole containing polyamide conjugates," Oncology Research (2003) 13(4):221-223
		KUMAR, R. et al., "Design and synthesis of novel pyrrolo[2,1-c][1,4]benzodiazepine - imidazole containing polyamide conjugates," Heterocyclic Communications (2002) 81(1):19-26
		KUMAR, R. et al., "Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo [2,1][1,4]benzodiazepine-glycosylated pyrrole and imidazole polyamide conjugates," Org. Biomol. Chem. (2003) 1(19):3327-3342
	✓	LANGLOIS, N. et al., "Synthesis and cytotoxicity on sensitive and doxorubicin-resistant cell lines of new pyrrolo[2,1-c][1,4]benzodiazepines related to anthramycin," J. Med. Chem. (2001) 44:3754-3757

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231.
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Unknown	
Sheet	4	of	5	Attorney Docket Number	065435-9027-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		LIPSHUTZ, B.H. et al., "Pd(II)_ Catalyzed Acetal/Ehtal Hydrolysis/Exchange Reactions," Tetrahedron Lett. (1985) 26(6):705-708
		MHAKA et al., "A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer," Biorg. Med. Chem. Lett. (2002) 12(17:2459-2461
		MISCHIATI, C. et al., "Binding of hybrid molecules containing pyrrolo [2,1-c][1,4]benzodiazepine (PBD) and oligopyrrole carriers to the human immunodeficiency type 1 virus TAR-RNA," Biochem. Pharmacol. (2004) 67(3):401-410
		MORI, M. et al., "Total syntheses of prothracarcin and tomaymycin by use of palladium catalyzed carbonylation," Tetrahedron (1986) 42(14):3793-3806
		MOUNTZOURIS, J.A. et al., "Comparison of a DSB-120 DNA interstrand cross-linked adduct with the corresponding bis-Tomamycin adduct," J. Med. Chem. (1994) 37:3132-3140
		NICULESCU-DUVAZ, D. et al., "Self-immolative nitrogen mustard prodrugs for suicide gene therapy," J. Med. Chem. (1998) 41(26):5297-5309
		REDDY et al., "Design, synthesis and in vitro cytotoxicity studies of novel pyrrolo[2,1-c][1,4]benzodiazepine (PBD)-polyamide conjugates and 2,2'-PBD dimers," Anti-Cancer Drug Design (2000) 15(3):225-228
		SPELLIE, M. et al., "Cellular pharmacology of novel C8-linked anthramycin-based sequence-selective DNA minor groove cross-linking agents," Br. J. Cancer (1994) 70:48-53
	↓	SPELLIE, M. et al., "Sequence selective recognition of duplex DNA through covalent interstrand cross-linking," Biochem. (2003) 42:8232-8239

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/602,521	
			Filing Date	June 24, 2003	
			First Named Inventor	David Edwin Thurston	
			Group Art Unit	1639	
			Examiner Name	Unknown	
Sheet	5	of	5	Attorney Docket Number	065435-9027-US00

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pages(s), volume-issue numbers(s), publisher, city and/or country where published.
/J.E./		THURSTON, D.E., "Nucleic acid targeting: therapeutic strategies for the 21st century," Brit. J. Cancer (1999) 80(1):65-85
/J.E./		TIBERGHEN, A.C. et al., "Application of the stille coupling reaction to the synthesis of C2-substituted endo-exo unsaturated pyrrolo[2,1-c][1,4]benzodiazepines (PBDs)," Biorg. Med. Chem. Lett. (2004) 14:5041-5044
/J.E./		WELLS, G. et al., "Pyrrolobenzodiazepine-polyamide libraries: synthesis and DNA binding selectivity," Proc. Am. Assoc. Canc. Res. (2003) 44:85-86, #452
/J.E./		WERMUTH et al., "Molecular Variations Based on Isosteric Replacements," The Practice of Medicinal Chemistry, Chapter 13 (1996) 203-237
/J.E./		WILLIAMS, M.A. et al., "Synthesis of conformationally constrained DTPA analogues. Incorporation of the ethylenediamine units as aminopyrrolidines," J. Org. Chem. (1994) 59(13):3616-3625

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
-----------------------	----------------	--------------------	------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number	10602521
Filing Date	2003-06-24
First Named Inventor	David Edwin Thurston
Art Unit	1639
Examiner Name	Jon D. Epperson
Attorney Docket Number	065435-9027 US00

U.S. PATENTS

Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

U.S. PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
/J.E./	1	20040062911		2004-04-01	Lauf et al.	

If you wish to add additional U.S. Published Application citation information please click the Add button.

FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
--------------------	---------	---	----------------

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number		10602521
Filing Date		2003-06-24
First Named Inventor	David Edwin Thurston	
Art Unit	1639	
Examiner Name	Jon D. Epperson	
Attorney Docket Number	065435-9027 US00	

/J.E./	1	GALLOP, M.A. et al., "Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries," J. Med. Chem. (1994) 37(9):1233-1251	<input type="checkbox"/>
/J.E./	2	GORDON, E.M. et al., "Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions," J. Med. Chem. (1994) 37(10):1385-1401	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	/Jon Epperson/	Date Considered	09/16/2007
--------------------	----------------	-----------------	------------

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.